CClinicalTrials.gg
CompletedNCT03057535Updated Feb 20, 2017

Impact of NaHCO3- on Exercise Hyperpnea

An Early Phase 1 interventional study of Sodium Bicarbonate and Sodium Chloride in Pulmonary Ventilation, sponsored by McGill University. Completed at 1 site in Canada. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-02-20.

Sponsored by McGill University · Early Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 9 months after the study started (first participant enrolled May 2015, registered Feb 2017).
Phase
Early Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

An abnormally high V̇E/V̇CO2 response to exercise is a key pathophysiological feature of patients with chronic cardiopulmonary disease that is associated with adverse health outcomes. It follows that any intervention capable of decreasing the V̇E/V̇CO2 response to exercise has the potential to improve clinical and/or patient-reported outcomes. The investigators of this trial will compare the effects of orally administered sodium chloride (4 g, placebo) and sodium bicarbonate (0.3 g/kg of body mass) on ventilation, breathing pattern, dynamic operating lung volume, gas exhange, cardiovascular, metabolic and symptom parameters during symptom-limited, high-intensity, constant-work-rate cycle exercise testing in healthy adults aged 20-40 years.

Read the detailed description

The ventilatory response (V̇E) to exercise-induced increases in the rate of CO2 production (V̇CO2) depends on the regulated level of arterial PCO2 (PaCO2) and the dead space to tidal volume ratio (VD/VT).

An abnormally high V̇E/V̇CO2 response to exercise, reflecting a high VD/VT and/or low PaCO2 equilibrium point, is a key pathophysiological feature of patients with chronic cardiopulmonary disease, including heart failure, pulmonary arterial hypertension, interstitial lung disease and chronic obstructive pulmonary disease. In these patient groups, exercise ventilatory inefficiency is associated with: disease severity and progression; exercise intolerance; exertional breathlessness; and increased risk of hospitalization, major cardiac events and mortality. It follows that any intervention capable of decreasing the V̇E/V̇CO2 response to exercise has the potential to improve clinical and/or patient-reported outcomes. Unfortunately, our ability to enhance exercise ventilatory efficiency is limited by the fact that, with the possible exception of lung volume reduction surgery in chronic obstructive pulmonary disease and pulmonary vasodilator therapy in pulmonary arterial hypertension and heart failure, ventilation-perfusion abnormalities reflecting a high VD/VT are often irreversible.

A largely unexplored approach to decreasing the V̇E/V̇CO2 response to exercise is increasing the PaCO2 equilibrium point by inducing a metabolic alkalosis via administration of an alkalizing agent such as sodium bicarbonate (NaHCO3). Thus, the primary objective of this randomized, double blind, placebo controlled, crossover study was to test the hypothesis that increasing the PaCO2 equilibrium point via induced acute metabolic alkalosis by single-dose oral administration of NaHCO3 would decrease in the V̇E/V̇CO2 ratio at its lowest point ("nadir") during high-intensity constant-load cycle exercise testing in healthy adults.

02

Conditions studied

  • Pulmonary Ventilation

Keywords

  • Exercise
  • Sodium Bicarbonate
  • Ventilatory equivalent for carbon dioxide
03

In context

Lead sponsor

McGill University is the lead sponsor of 244 studies on the registry; 49 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Healthy
  • Non-smoking
  • Habitually active
  • Non-obese (Body Mass Index \<30 kg/m2)
  • Normal lung function on spirometry

Exclusion criteria

Exclusion Criteria:

  • Self-reported gastrointestinal, cardiovascular, vascular, respiratory, kidney, liver, musculoskeletal, endocrine, neuromuscular and/or metabolic disease/dysfunction
  • Taking doctor prescribed medications other than oral contraceptives
05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Sodium Bicarbonate

    Ingestion of sodium bicarbonate (0.3 g/kg of body mass)

    Drug: Sodium Bicarbonate

  • Placebo comparator
    Sodium Chloride

    Ingestion of sodium chloride (4 g)

    Drug: Sodium Chloride

Interventions

  • DrugSodium Bicarbonate
  • DrugSodium Chloride
06

What researchers measure

Primary outcomes

  1. Ventilatory equivalent to carbon dioxide (V̇E/V̇CO2) at its lowest point ("nadir") during exercise

    The V̇E/V̇CO2 nadir will be identified as the lowest 30-sec average data point during constant-load cycle exercise testing

    Time frame: Participants will be followed until all study visits are complete, an expected average of 3 weeks

Secondary outcomes

  1. Partial pressure of carbon dioxide in the arterialized capillary blood (PacCO2)

    PacCO2 (mmHg) will be measured at rest 90-min post-dose

    Time frame: Time Frame: Participants will be followed until all study visits are complete, an expected average of 3 weeks

07

Study locations

1 site
  • McGill University, Department of Kinesiology & Physical Education, Clinical Exercise & Respiratory Physiology Laboratory
    Montreal, Quebec H2W 1S4, Canada
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03057535
Lead sponsor
McGill University
Responsible party
Dennis Jensen, Ph.D. (Assistant Professor, McGill University) — Principal investigator
First posted
Feb 20, 2017
Start date
May 2015
Primary completion
Apr 2016
Completion
Sep 2016
Last update
Feb 20, 2017

Study contacts

Dennis Jensen, Ph.D.
principal investigator · McGill University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion